GE HealthCare TechnologiesMEX:GEHC 63 Altman Z2-Score is 1.81 as of Jun. 28, 2026, which is 27% above its 10-year median of 1.42. GuruFocus rates MEX:GEHC with a GF Score™ of 63/100 and a GF Value™ of MXN1,368.40 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 846 Medical Devices & Instruments companies, GE HealthCare Technologies ranks worse than 61.11% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
GE HealthCare Technologies has a Altman Z2-Score of 1.81, indicating it is in Grey Zones. This implies that GE HealthCare Technologies is in some kind of financial stress. If it is below 1.1, the company may face bankrupcy risk.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for GE HealthCare Technologies's Altman Z2-Score or its related term are showing as below:
MEX:GEHC'
s Altman Z2-Score Range Over the Past 10 Years
Min: 1.12 Med: 1.42 Max: 2.75
Current: 1.8
During the past 7 years, GE HealthCare Technologies's highest Altman Z2-Score was 2.75. The lowest was 1.12. And the median was 1.42.
GE HealthCare Technologies (MEX:GEHC) Altman Z2-Score Explanation
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GEHC vs DXCM, STE, ZBH: Altman Z2-Score Comparison
For the Medical Devices subindustry, GE HealthCare Technologies's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GE HealthCare Technologies Altman Z2-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, GE HealthCare Technologies's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where GE HealthCare Technologies's Altman Z2-Score falls into.
GE HealthCare Technologies Altman Z2-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
GE HealthCare Technologies (MEX:GEHC) has a Altman Z2-Score of 1.81 as of Jun. 28, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on GE HealthCare Technologies and its competitors. This is 27% above median its historical median of 1.42. Over the past decade, GE HealthCare Technologies' Altman Z2-Score has ranged from 1.12 to 2.75. According to the industry distribution chart, GE HealthCare Technologies ranks #517 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 61.1%.
Is GE HealthCare Technologies' Altman Z2-Score too high?
GE HealthCare Technologies' current Altman Z2-Score of 1.81 is 27% above median its 10-year median of 1.42. Over the past 10 years, this metric has ranged from a low of 1.12 to a high of 2.75. The Medical Devices & Instruments industry median Altman Z2-Score is 3.48. GE HealthCare Technologies' value of 1.81 is 48% below this industry median. Based on the distribution chart, GE HealthCare Technologies ranks #517 out of 846 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, GE HealthCare Technologies has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GE HealthCare Technologies' Altman Z2-Score compare to DXCM and STE?
According to the Medical Devices & Instruments industry distribution chart, GE HealthCare Technologies ranks #517 out of 846 companies for Altman Z2-Score. This places GE HealthCare Technologies in the lower half of its industry. The industry median Altman Z2-Score is 3.48. GE HealthCare Technologies' value of 1.81 is 48% below this benchmark. Historically, GE HealthCare Technologies' own Altman Z2-Score has ranged from 1.12 to 2.75 over the past decade. While the company's 10-year median is 1.42 vs. the industry median of 3.48, GE HealthCare Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Devices & Instruments company?
The median Altman Z2-Score among Medical Devices & Instruments companies is 3.48, based on 846 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GE HealthCare Technologies's current Altman Z2-Score of 1.81 is 48% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on GE HealthCare Technologies and its competitors. For the Medical Devices & Instruments industry, the median Altman Z2-Score is 3.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GE HealthCare Technologies's current Altman Z2-Score is 1.81, which is 27% above median its own 10-year median of 1.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GE HealthCare Technologies stock overvalued right now?
Based on GuruFocus' analysis, GE HealthCare Technologies (MEX:GEHC) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN1,368.40, compared to a current price of MXN1,058.16 — trading 22.7% below its estimated fair value. The current Altman Z2-Score is 1.81, which is 27% above median its 10-year median of 1.42 and 48% below the Medical Devices & Instruments industry median of 3.48. GE HealthCare Technologies' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For GE HealthCare Technologies (MEX:GEHC), the current Altman Z2-Score is 1.81 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GE HealthCare Technologies (MEX:GEHC) Overvalued in 2026?
Based on GuruFocus' analysis, GE HealthCare Technologies stock appears to be undervalued.
The current stock price of MXN1,058.16 is trading 22.7% below its estimated GF Value™ of MXN1,368.40.
GuruFocus considers GE HealthCare Technologies to be Modestly Undervalued.
Key valuation signals for MEX:GEHC:
Altman Z2-Score: 1.81 (27% above median its 10-year median of 1.42)
GF Value™: MXN1,368.40 vs. price of MXN1,058.16 (22.7% below fair value)
Industry Position: 48% below the Medical Devices & Instruments median (#517 of 846)
No single metric tells the full story. See the MEX:GEHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
63GF Score
Get the complete analysis for MEX:GEHC
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GEHC has been successfully added to your 
